



Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-19	119	PDF
Single User	Multi User	Enterprise	
USD 2,950	USD 4,430	USD 5,900	

Description

The global Tumor Necrosis Factor Receptor Superfamily Member 9 market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Tumor Necrosis Factor Receptor Superfamily Member 9 market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tumor Necrosis Factor Receptor Superfamily Member 9 market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tumor Necrosis Factor Receptor Superfamily Member 9 market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tumor Necrosis Factor Receptor Superfamily Member 9 include Eli Lilly and Co, Pfizer Inc, Pieris Pharmaceuticals Inc, MacroGenics Inc, Juno Therapeutics Inc, BioInvent International AB, Apogenix GmbH, Alligator Bioscience AB and Agenus Inc. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Tumor Necrosis Factor Receptor Superfamily Member 9 market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tumor Necrosis Factor Receptor Superfamily Member 9.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Tumor Necrosis Factor Receptor Superfamily Member 9 Market by Company

Eli Lilly and Co

Pfizer Inc

Pieris Pharmaceuticals Inc

MacroGenics Inc
Juno Therapeutics Inc
BioInvent International AB
Apogenix GmbH
Alligator Bioscience AB
Agenus Inc

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Type

Ultra-41BBL
PRS-342
ISAS-01
EU-101
Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Application

Gastric Cancer
Lymphoma
Cervical Cancer
Bladder Cancer
Others

Tumor Necrosis Factor Receptor Superfamily Member 9 Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Necrosis Factor Receptor Superfamily Member 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Necrosis Factor Receptor Superfamily Member 9.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Tumor Necrosis Factor Receptor Superfamily Member 9 companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Ultra-41BBL
 - 2.2.3 PRS-342
 - 2.2.4 ISAS-01
 - 2.2.5 EU-101
 - 2.2.6 Others
- 2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Gastric Cancer
 - 2.3.3 Lymphoma
 - 2.3.4 Cervical Cancer
 - 2.3.5 Bladder Cancer
 - 2.3.6 Others
- 2.4 Assumptions and Limitations

3 Tumor Necrosis Factor Receptor Superfamily Member 9 Breakdown Data by Type

- 3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Type (2021-2026)
- 3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Type (2027-2032)

4 Tumor Necrosis Factor Receptor Superfamily Member 9 Breakdown Data by Application

- 4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Application (2021-2026)
- 4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Perspective (2021-2032)
- 5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Growth Trends by Region
 - 5.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Region (2021-2026)
 - 5.2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Region (2027-2032)
- 5.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Dynamics
 - 5.3.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends
 - 5.3.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Drivers
 - 5.3.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Challenges
 - 5.3.4 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Restraints

6 Market Competitive Landscape by Players

- 6.1 Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Revenue
 - 6.1.1 Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Revenue (2021-2026)
 - 6.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Players (2021-2026)
- 6.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Tumor Necrosis Factor Receptor Superfamily Member 9 Head Office and Area Served
- 6.4 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Players, Product Type & Application
- 6.5 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Manufacturers Established Date
- 6.6 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition

7 North America

- 7.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 7.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 7.4 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico

8 Europe

- 8.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 8.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 8.4 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries

9 Asia-Pacific

- 9.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 9.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia

10 South America

- 10.1 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 10.2 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 10.4 South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru

11 Middle East & Africa

- 11.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2021-2032)
- 11.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt

12 Players Profiled

- 12.1 Eli Lilly and Co
 - 12.1.1 Eli Lilly and Co Company Information
 - 12.1.2 Eli Lilly and Co Business Overview
 - 12.1.3 Eli Lilly and Co Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - 12.1.4 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
 - 12.1.5 Eli Lilly and Co Recent Developments
- 12.2 Pfizer Inc
 - 12.2.1 Pfizer Inc Company Information
 - 12.2.2 Pfizer Inc Business Overview
 - 12.2.3 Pfizer Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - 12.2.4 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
 - 12.2.5 Pfizer Inc Recent Developments
- 12.3 Pieris Pharmaceuticals Inc
 - 12.3.1 Pieris Pharmaceuticals Inc Company Information
 - 12.3.2 Pieris Pharmaceuticals Inc Business Overview
 - 12.3.3 Pieris Pharmaceuticals Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - 12.3.4 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
 - 12.3.5 Pieris Pharmaceuticals Inc Recent Developments
- 12.4 MacroGenics Inc
 - 12.4.1 MacroGenics Inc Company Information
 - 12.4.2 MacroGenics Inc Business Overview
 - 12.4.3 MacroGenics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - 12.4.4 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
 - 12.4.5 MacroGenics Inc Recent Developments

12.5 Juno Therapeutics Inc

- 12.5.1 Juno Therapeutics Inc Company Information
- 12.5.2 Juno Therapeutics Inc Business Overview
- 12.5.3 Juno Therapeutics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.5.4 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.5.5 Juno Therapeutics Inc Recent Developments

12.6 BioInvent International AB

- 12.6.1 BioInvent International AB Company Information
- 12.6.2 BioInvent International AB Business Overview
- 12.6.3 BioInvent International AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.6.4 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.6.5 BioInvent International AB Recent Developments

12.7 Apogenix GmbH

- 12.7.1 Apogenix GmbH Company Information
- 12.7.2 Apogenix GmbH Business Overview
- 12.7.3 Apogenix GmbH Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.7.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.7.5 Apogenix GmbH Recent Developments

12.8 Alligator Bioscience AB

- 12.8.1 Alligator Bioscience AB Company Information
- 12.8.2 Alligator Bioscience AB Business Overview
- 12.8.3 Alligator Bioscience AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.8.4 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.8.5 Alligator Bioscience AB Recent Developments

12.9 Agenus Inc

- 12.9.1 Agenus Inc Company Information
- 12.9.2 Agenus Inc Business Overview
- 12.9.3 Agenus Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
- 12.9.4 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- 12.9.5 Agenus Inc Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2021-2026)
- Table 7: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2027-2032)
- Table 9: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Application (2021-2026)
- Table 11: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Application (2027-2032)
- Table 13: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2021-2026)
- Table 16: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2027-2032)
- Table 18: Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Trends
- Table 19: Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Drivers
- Table 20: Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Opportunities and Challenges
- Table 21: Tumor Necrosis Factor Receptor Superfamily Member 9 Market Restraints
- Table 22: Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Players (2021-2026)
- Table 24: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Tumor Necrosis Factor Receptor Superfamily Member 9, Headquarters and Area Served
- Table 26: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Tumor Necrosis Factor Receptor Superfamily Member 9 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS

2025 VS 2032 (US\$ Million)

- Table 40: South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Eli Lilly and Co Company Information
- Table 46: Eli Lilly and Co Business Overview
- Table 47: Eli Lilly and Co Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 48: Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 49: Eli Lilly and Co Recent Developments
- Table 50: Pfizer Inc Company Information
- Table 51: Pfizer Inc Business Overview
- Table 52: Pfizer Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 53: Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 54: Pfizer Inc Recent Developments
- Table 55: Pieris Pharmaceuticals Inc Company Information
- Table 56: Pieris Pharmaceuticals Inc Business Overview
- Table 57: Pieris Pharmaceuticals Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 58: Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 59: Pieris Pharmaceuticals Inc Recent Developments
- Table 60: MacroGenics Inc Company Information
- Table 61: MacroGenics Inc Business Overview
- Table 62: MacroGenics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 63: MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 64: MacroGenics Inc Recent Developments
- Table 65: Juno Therapeutics Inc Company Information
- Table 66: Juno Therapeutics Inc Business Overview
- Table 67: Juno Therapeutics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 68: Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 69: Juno Therapeutics Inc Recent Developments
- Table 70: BioInvent International AB Company Information
- Table 71: BioInvent International AB Business Overview
- Table 72: BioInvent International AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 73: BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 74: BioInvent International AB Recent Developments
- Table 75: Apogenix GmbH Company Information
- Table 76: Apogenix GmbH Business Overview
- Table 77: Apogenix GmbH Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 78: Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 79: Apogenix GmbH Recent Developments
- Table 80: Alligator Bioscience AB Company Information
- Table 81: Alligator Bioscience AB Business Overview
- Table 82: Alligator Bioscience AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 83: Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 84: Alligator Bioscience AB Recent Developments
- Table 85: Agenus Inc Company Information
- Table 86: Agenus Inc Business Overview
- Table 87: Agenus Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026) & (US\$ Million)
- Table 88: Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product Portfolio
- Table 89: Agenus Inc Recent Developments

- Table 90: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Tumor Necrosis Factor Receptor Superfamily Member 9 Product Image
- Figure 5: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type: 2025 VS 2032
- Figure 7: Ultra-41BBL Product
- Figure 8: PRS-342 Product
- Figure 9: ISAS-01 Product
- Figure 10: EU-101 Product
- Figure 11: Others Product
- Figure 12: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 13: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application: 2025 VS 2032
- Figure 14: Gastric Cancer Product
- Figure 15: Lymphoma Product
- Figure 16: Cervical Cancer Product
- Figure 17: Bladder Cancer Product
- Figure 18: Others Product
- Figure 19: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 20: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 21: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region: 2025 VS 2032
- Figure 22: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Players in 2025
- Figure 23: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Manufacturers Established Date
- Figure 24: Global Top 5 and 10 Tumor Necrosis Factor Receptor Superfamily Member 9 Players Market Share by Revenue in 2025
- Figure 25: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 26: North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 27: North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
- Figure 28: United States Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
- Figure 31: Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
- Figure 33: Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: France Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Spain Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Netherlands Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Nordic Countries Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
- Figure 43: China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$

- Million)
- Figure 45: South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 46: India Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 47: India Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
 - Figure 48: Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 49: China Taiwan Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 50: Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 51: South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 52: South America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2021-2032)
 - Figure 53: Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 54: Argentina Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 55: Chile Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 56: Colombia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 57: Peru Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2021-2032) & (US\$ Million)
 - Figure 58: Eli Lilly and Co Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 59: Pfizer Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 60: Pieris Pharmaceuticals Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 61: MacroGenics Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 62: Juno Therapeutics Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 63: BioInvent International AB Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 64: Apogenix GmbH Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 65: Alligator Bioscience AB Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)
 - Figure 66: Agenus Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2021-2026)